Sign in

CIK 0001840229

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

MiNK Therapeutics, Inc.

Sign in to watch
Ticker
INKT
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 212-994-8250
Business address
149 FIFTH AVENUE, SUITE 500, NEW YORK, NY, 10010
Former names
AgenTus Therapeutics, Inc., AgenTus Therapeutics, Inc.
  1. 4 Open-market buy 10% owner bought 45,426 shares at an average $1.47 ($66,644)
  2. 4 Open-market sale Director sold 100,000 shares at $0.95 ($94,850)
  3. 4 Open-market buy 10% owner bought 250,362 shares at an average $1.04 ($260,189)
  4. 4 Open-market buy Director bought 100,000 shares at $0.95 ($94,850)
  5. 4 Other disposition 10% owner disposed of 4,988,273 shares (other)
  6. 4 Grant or award Director acquired 6,699 shares (grant or award)
  7. 4 Grant or award Director acquired 8,553 shares (grant or award)
  8. 4 Grant or award Director acquired 6,878 shares (grant or award)
  9. 4 Grant or award Director acquired 8,493 shares (grant or award)
  10. 4 Grant or award Director acquired 7,357 shares (grant or award)
  11. 4 Derivatives Options or other derivatives
  12. 4 Grant or award Chief Scientific Officer acquired 51,628 shares (grant or award)
  13. 4 Derivatives Options or other derivatives
  14. 4 Grant or award Chief Executive Officer acquired 171,990 shares (grant or award)
  15. 4 Grant or award Director acquired 5,364 shares (grant or award)
  16. 4 Grant or award Director acquired 5,508 shares (grant or award)
  17. 4 Grant or award Director acquired 6,849 shares (grant or award)
  18. 4 Grant or award Director acquired 6,801 shares (grant or award)
  19. 4 Grant or award Director acquired 5,891 shares (grant or award)
  20. 4 Grant or award Director acquired 10,974 shares (grant or award)

Page 6 of 8 · 145 filings